SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    National Cancer Institute; Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence—SEER 17 Registries Research Data + Hurricane Katrina-Impacted Louisiana Cases: November 2010 Submission (2000-2008), Linked to County Attributes, Total US, 1969-2009 Counties. Bethesda, MD: National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch; released April 2011 [based on the November 2010 submission]. Available at: http://www.seer.cancer.gov. Accessed October 5, 2011 using SEER*Stat software.
  • 2
    Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence-SEER 9 Registries Research Data, November 2010 Submission (1973-2008): Katrina/Rita Population Adjustment-Linked to County Attributes, Total US, 1969-2009 Counties. Bethesda, MD: National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch; released April 2011 [based on the November 2010 submission]. Available at: http://www.seer.cancer.gov. Accessed October 5, 2011 using SEER*Stat software.
  • 3
    National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin's Lymphomas. Version 1.2010. Fort Washington, PA: NCCN; 2010.
  • 4
    Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002; 346: 235-242.
  • 5
    Habermann T, Weller E, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006; 24: 3121-3127.
  • 6
    Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomized controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006; 7: 379-391.
  • 7
    Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood. 2010; 116: 2040-2045.
  • 8
    Bach P. Limits on Medicare's ability to control rising spending on cancer drugs. N Engl J Med. 2009; 360: 626-633.
  • 9
    Medicare Payment Advisory Commission (MedPAC). A Data Book: Health Care Spending and the Medicare Program (June 2011). Reston, VA: MedPAC; 2011. Available at: http://www.medpac.gov/chapters/Jun11DataBookSec10.pdf. Accessed October 20, 2011.
  • 10
    Griffiths RI, Gleeson ML, Mikhael JR, Danese MD. Long-term direct medical costs in patients diagnosed with follicular lymphoma who receive frontline chemotherapy with versus without rituximab—a SEER-Medicare analysis. Paper presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 16th Annual Meeting; Baltimore, MD; May 21-25, 2011.
  • 11
    Hornberger JC, Best JH. Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma. Cancer. 2005; 103: 1644-1651.
  • 12
    Groot MT, Lugtenburg PJ, Hornberger J, Huijgens PC, Uyl-de Groot CA. Cost-effectiveness of rituximab (MabThera®) in diffuse large B-cell lymphoma in the Netherlands. Eur J Haematol. 2005; 74: 194-202.
  • 13
    Best JH, Hornberger J, Proctor SJ, Omnes LF, Jost F. Cost-effectiveness analysis of rituximab combined with CHOP for treatment of diffuse large B-cell lymphoma. Value Health. 2005; 8: 462-470.
  • 14
    Ferrara F, Ravasio R. Cost-effectiveness analysis of the addition of rituximab to CHOP in young patients with good-prognosis diffuse large B-cell lymphoma. Clin Drug Invest. 2008; 28: 55-65.
  • 15
    Johnston KM, Marra CA, Connors JM, Najafzadeh M, Sehn L, Peacock SJ. Cost-effectiveness of the addition of rituximab to CHOP chemotherapy in first-line treatment for diffuse large B-cell lymphoma in a population-based observational cohort in British Columbia, Canada. Value Health. 2010; 13: 703-711.
  • 16
    Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002; 40( 8 suppl)): IV-3-IV-18.
  • 17
    National Cancer Institute. Overview of the SEER Program. Bethesda, MD: National Cancer Institute; 2011. Available at: http://seer.cancer.gov/about/overview.html. Accessed September 29, 2011.
  • 18
    National Cancer Institute. Overview of the SEER Program. Bethesda, MD: National Cancer Institute; 2011. Available at: http://healthservices.cancer.gov/seermedicare/overview/linked.html. Accessed September 29, 2011.
  • 19
    North American Association of Central Cancer Registries. Guidelines for ICD-O-3 implementation. November 27, 2000. Available at: http://www.naacr.org. Accessed February 24, 2011.
  • 20
    [No authors listed] A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993; 329: 987-994.
  • 21
    Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982; 5: 649-655.
  • 22
    Davidoff AJ, Tang M, Seal B, Edelman MJ. Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol. 2010; 28: 2191-2197.
  • 23
    Danese MD, Griffiths RI, Gleeson M, et al. An observational study of outcomes after initial infused therapy in Medicare patients diagnosed with chronic lymphocytic leukemia. Blood. 2011; 117: 3505-3513.
  • 24
    Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000; 53: 1258-1267.
  • 25
    Klabunde CN, Legler JM, Warren JL, Baldwin L-M, Schrag D. A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients. Ann Epidemiol. 2007; 17: 584-590.
  • 26
    Warren JL, Harlan LC, Fahey A, et al. Utility of the SEER-Medicare data to identify chemotherapy use. Med Care. 2002; 40( 8 suppl): IV-55-IV-61.
  • 27
    National Cancer Institute. Procedure Codes for SEER Medicare Analysis. Bethesda, MD: National Cancer Institute; 2010. Available at: http://healthservices.cancer.gov/seermedicare/considerations/procedure_codes.html. Accessed December 7, 2010.
  • 28
    Yabroff KR, Lamont EB, Mariotto A, et al. Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst. 2008; 100: 630-641.
  • 29
    Rubin DR. Estimating causal effects from large data sets using propensity scores. Ann Intern Med. 1997; 127: 757-763.
  • 30
    Xie J, Liu C. Adjusted Kaplan-Meier estimator and log-rank test with inverse probability of treatment weighting for survival data. Stat Med. 2005; 24: 3089-3110.
  • 31
    Bang H, Tsiatis AA. Estimating medical costs with censored data. Biometrika. 2000; 87: 329-343.
  • 32
    Lin DY. Linear regression analysis of censored medical costs. Biostatistics. 2000; 1: 35-47.
  • 33
    Efron B, Tibshirani RJ. An Introduction to the Bootstrap. Chapman & Hall Monographs on Statistics and Applied Probability. Boca Raton, FL: Chapman & Hall/CRC Press; 1994.
  • 34
    Giordano SH, Kuo Y-F, Duan Z, Hortobagyi GN, Freeman J, Goodwin JS. Limits of observational data in determining outcomes from cancer therapy. Cancer. 2008; 112: 2456-2466.